Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Griffiths, R, Gleeson, M, Mikhael, J, Danese, MD
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2012

Eitemau Tebyg

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma
gan: Griffiths, R, et al.
Cyhoeddwyd: (2012)

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2012)

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2011)

Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2012)

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2010)

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2012)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
gan: Ulrich Dührsen, et al.
Cyhoeddwyd: (2018-07-01)

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.
gan: Danese, MD, et al.
Cyhoeddwyd: (2011)

Rituximab maintenance therapy: a step forward in follicular lymphoma
gan: Marinus H.J. van Oers
Cyhoeddwyd: (2007-06-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
gan: Vibor Milunović, et al.
Cyhoeddwyd: (2017-01-01)

Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
gan: Danese, MD, et al.
Cyhoeddwyd: (2016)

Life-threatening Pneumocystis jiroveci Pneumonia with Cytomegalovirus Coinfection in a Follicular Lymphoma Patient During Rituximab-based Chemotherapy
gan: Mu-Chun Yang, et al.
Cyhoeddwyd: (2024-01-01)

Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
gan: Wulyo Rajabto, et al.
Cyhoeddwyd: (2024-04-01)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma
gan: Klaus Herfarth, et al.
Cyhoeddwyd: (2018-12-01)

FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
gan: Alessia Castellino, et al.
Cyhoeddwyd: (2017-01-01)

Managing Follicular Lymphoma in the Elderly Population
gan: Jiao Jie Cherie Tan, et al.
Cyhoeddwyd: (2023-01-01)

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
gan: Ulrich Jäger, et al.
Cyhoeddwyd: (2012-09-01)

Rituximab and dose dense chemotherapy in primary breast lymphoma
gan: Agustin Avilés, et al.
Cyhoeddwyd: (2007-08-01)

Comparative Costs to Medicare and Medicare Beneficiaries of Alternative AF Stroke Risk Reduction Strategies
gan: Reddy VY, et al.
Cyhoeddwyd: (2024-02-01)

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
gan: W. Townsend, et al.
Cyhoeddwyd: (2022-06-01)

Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
gan: Powe, N, et al.
Cyhoeddwyd: (1993)

Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma
gan: Nathan H. Fowler, et al.
Cyhoeddwyd: (2020-09-01)

Cumulative reproduction and survival costs in female red deer
gan: Moyes, K, et al.
Cyhoeddwyd: (2006)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
gan: Natalia Sadetsky, et al.
Cyhoeddwyd: (2020-09-01)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
gan: Griffiths, R, et al.
Cyhoeddwyd: (2010)

P1738: A SEER-MEDICARE ANALYSIS OF THE ECONOMIC BURDEN AMONG ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
gan: A. McBride, et al.
Cyhoeddwyd: (2022-06-01)

Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study
gan: Wenshuai Zheng, et al.
Cyhoeddwyd: (2024-04-01)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
gan: Silvana Novelli, et al.
Cyhoeddwyd: (2023-08-01)

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review
gan: Chao Wang, et al.
Cyhoeddwyd: (2025-01-01)

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
gan: Griffiths, R, et al.
Cyhoeddwyd: (2012)

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study
gan: C. Madsen, et al.
Cyhoeddwyd: (2018-07-01)

Follicular lymphoma
gan: Ellen Leich, (Coordinating Author)
Cyhoeddwyd: (2019-06-01)

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
gan: Jan Dürig, et al.
Cyhoeddwyd: (2023-02-01)

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
gan: Sikander Ailawadhi, et al.
Cyhoeddwyd: (2019-10-01)

A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma
gan: Ceri Morgan, et al.
Cyhoeddwyd: (2015-01-01)

Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries
gan: Namino M. Glantz, et al.
Cyhoeddwyd: (2019-05-01)

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study
gan: Judith Trotman, et al.
Cyhoeddwyd: (2023-03-01)

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database
gan: Huai‐Hsuan Huang, et al.
Cyhoeddwyd: (2018-08-01)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
gan: L. H. Sehn, et al.
Cyhoeddwyd: (2022-06-01)

Follicular lymphoma genomics
gan: Emil Kumar, et al.
Cyhoeddwyd: (2019-06-01)